TNFRSF1A and myeloid sarcoma: MS patients with NLRP3 low-penetrance variants (n = 4; 21%) suffered less frequently from gastrointestinal symptoms compared to MS patients with TNFRSF1A variants (n = 36; 62%, p = 0.0169).